Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

As Chief Audit Officer of Novartis, Teresa and her team provide risk-based assurance and advice on key strategic topics to ...

Novartis has been serving patients in Indonesia for more than 50 years, through our predecessor companies, Ciba and Sandoz.

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common ...

This study has the purpose to answer how the Lipoprotein (a) (Lp (a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between ...

Treating advanced prostate cancer demands more than clinical progress—it demands a new era of care, fueled by relentless innovation, collaborative efforts, and an unwavering push toward personalized ...

【報道関係者各位】ノバルティス ファーマ株式会社の2025年6月24日付けプレスリリース『ノバルティス ファーマとがん研有明病院が治験に関する戦略的パートナーシップ協定を締結 ― 患者さんの治験への参加機会の拡大と効率化を目指す新たな協力体制 ―』です。

Despite endocrine therapy (ET), the risk of recurrence for people diagnosed with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (eBC) ...

this week to discuss new ideas to transform healthcare. Our Novartis leaders engaged in discussions showcasing the company's scientific breakthroughs—and shared something just as urgent: The story of ...

Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...

. Novartis blijft daarnaast fundamenteel van mening verschillen over de door de zorgverzekeraars gestelde therapeutische uitwisselbaarheid van de CDK4/6-remmers. Wij blijven van mening dat medisch ...